Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 3/2014

01-03-2014 | New Imaging Techniques (A Atala and A Rastinehad, Section Editors)

Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential

Authors: Ansje S Fortuin, Robert Jan Smeenk, Hanneke JM Meijer, Alfred J Witjes, Jelle O Barentsz

Published in: Current Urology Reports | Issue 3/2014

Login to get access

Abstract

Nodal staging in prostate cancer is suboptimal both with respect to current imaging modalities and pelvic lymph node dissection, and thus other techniques are being explored. Lymphotropic nanoparticle-enhanced MRI, also called magnetic resonance lymphography (MRL), is a technique that has shown high sensitivity (65–92 %) and excellent specificity (93–98 %) in detecting prostate cancer lymph node metastases. This technique aids in the detection of metastases in non-enlarged small nodes. MRL has been useful in determining the location and pathways of spread in nodal chains. Knowledge of the location of lymph node involvement is important for decisions regarding appropriate therapeutic options, such as image-guided therapy.. A geographic miss in radiotherapy can be avoided with the use of MRL-guided focal therapy. This paper provides an overview of current literature, lessons learned, and new therapeutic options with nanoparticle-enhanced MRI.
Literature
1.
Hövels A, Heesakkers R, Adang E, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin rad. 2008;63:387–95.CrossRef
2.
Heesakkers R, Jager G, Hövels A, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR Imaging. Radiology. 2009;251:408–14.PubMedCrossRef
3.••
Joniau S, van den Bergh L, Lerut E, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur urol. 2013;63:450–8. In this article, lymphatic drainage and discrimination patterns of prostate cancer were presented. Standard PLND would have correctly staged the majority of lymph node-positive patients, but 13% of the positive lymph nodes would be missed..PubMedCrossRef
4.
Makarov D, Trock B, Humphreys E, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason Score (Partin tables) based on cases from 2000–2005. Urology. 2007;69:1095–101.PubMedCentralPubMedCrossRef
5.
Roach III M, Marquez C, You H. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33–7.PubMedCrossRef
6.
Deserno W, Debats O, Rozema T, et al. Comparison of nodal risk formula and MR Lymphography for predicting lymph node involvement in prostate cancer. Int J Rad Oncol Biol Phys. 2011;81:8–15.CrossRef
7.
Nguyen P, Chen M, Hoffman K, et al. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys. 2009;74:104–9.PubMedCrossRef
8.
Bellin MF, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. Eur J Rad. 2000;34:257–64.CrossRef
9.
Fortuin A, Deserno W, Meijer H, et al. Value of PET/CT and MR Lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Rad Oncol Biol Phys. 2012;84:712–8.CrossRef
10.
Harisinghani MG, Saini S, Weissleder R, et al. Ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathological correlation. AJR. 1999;172:1347–51.PubMedCrossRef
11.
Harisinghani M, Barentsz J, Hahn P, et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol. 2002;9:s312–3.PubMedCrossRef
12.
Harisinghani M, Barentsz J, Hahn P, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–9.PubMedCrossRef
13.
Deserno WMLLG, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004;233:449–56.PubMedCrossRef
14.
Tabatabaei S, Harisinghani MG, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol. 2005;174:923–7.PubMedCrossRef
15.
Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphtrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology. 2005;66:1066–71.PubMedCrossRef
16.
Harisinghani MG, Saksena MA, Hahn PF, et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR. 2006;186:144–8.PubMedCrossRef
17.
Guimaraes AR, Tabatabei S, Dahl D, et al. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology. 2008;71:708–12.PubMedCrossRef
18.
Heesakkers R, Hovels A, Jager G, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9:850–6.PubMedCrossRef
19.
Thoeny H, Triantafyllou M, Birkhäuser F, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761–9.PubMedCrossRef
20.
Triantafyllou M, Studer U, Birkhäuser F, et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer. 2013;49:616–24.PubMedCrossRef
21.•
Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 2013; in press. Most recent article on MRL, with the addition of a DWI sequence to the protocol, resulting in reduction of reading time.
22.
Wu L, Cao Y, Liao C, Huang J, Gao F. Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: a meta-analysis. Eur J Rad. 2011;80:582–9.CrossRef
23.
Fortuin AS, Meijer H, Thomson LC, Witjes JA, Barentsz JO. Ferumoxtran-10 (USPIO)-enhanced DWI-MRI for detection of metastases in normal-sized lymph nodes in patients with bladder and prostate cancer: do we enter the era after ePLND? Editorial. Eur Urol. 2013; in press.
24.
Fortuin A, Barentsz J. Comments on Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer. 2013;49:1789–90.PubMedCrossRef
25.
Evangelista L, Guttilla A, Zattoni F, et al. Utility of choline positron tomography/computed tomography for lymph node involvement identification in intermediate-to-high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63:1040–8.PubMedCrossRef
26.
Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [11C] choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013; Epub ahead of print.
27.
Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68GA]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.PubMedCrossRef
28.
Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.PubMedCrossRef
29.
Afshar-Oromieh A, Haberkorn U, Hadaschik B. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013; Epub ahead of print.
30.
Roethke M, Kuru TH, Afshar-Oromieh A, et al. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. 2013; Epub ahead of print.
31.
Banerjee S, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41.PubMedCentralPubMedCrossRef
32.
Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [68GA]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012; 39:1085–1086.
33.••
Meijer H, Fortuin A, van Lin E, et al. Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiother Oncol. 2013;106:59–63. MRL-based study presenting the distribution of lymph node metastases in primary prostate cancer patients. 53% of patients had a positive lymph node outside the standard radiation field.PubMedCrossRef
34.••
Meijer H, Van Lin E, Debats O, et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy 2012. Int J Rad Oncol Biol Phys. 2012;82:1405–10. MRL-based study presenting the distribution of lymph node metastases in prostate cancer patients with recurrence. 79% of patients had at least one positive lymph node outside the standard radiation field..CrossRef
35.
Joslyn S, Konety B. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006;68:121–5.PubMedCrossRef
36.
Burkhard F, Studer U. The role of lymphadenectomy in high-risk prostate cancer. World J Urol. 2008;26:231–6.PubMedCrossRef
37.
Thurairaja R, Studer U, Burkhard F. Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist. 2009;14:40–51.PubMedCrossRef
38.
Allaf M, Palapattu G, Trock B, Carter H, Walsh P. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172:1840.PubMedCrossRef
39.
Cheng L, Zincke H, Blute M, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. American cancer society. 2001;91:66–73.
40.
Fleischmann A, Schobinger S, Schumacher M, Thalmann G, Studer U. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate. 2009;69:352–62.PubMedCrossRef
41.
Meijer H, Debats O, van Lin E, et al. A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured? Radiat Oncol. 2013; 8: Epub ahead of print.
42.
RTOG 94–13 A phase III trial comparing whole pelvic irradiation followed by a conedown boost to boost irradiation only and comparing neoadjuvant to adjuvant total androgen suppression (TAS).
43.
Adkinson J, McHaffie D, Bentzen S, et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:184–90.CrossRef
44.
Ganswindt U, Paulsen F, Corvin S, et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer. 2005;5:91.PubMedCentralPubMedCrossRef
45.
Meijer H, Debats O, Kunze-Busch M, et al. Magnetic resonance lymphography-guided selective high dose lymph node irradiation in prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:175–83.PubMedCrossRef
46.
Meijer H, Debats O, van Lin E, et al. Individualized image-based lymph node irradiation for prostate cancer. Nat Rev Urol. 2013;10:376–85.PubMedCrossRef
47.
Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011; 6:44.
48.
Weidner A, van Lin E, Dinter D, et al. Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse. Strahlenther Oncol. 2011;187:206–2012.CrossRef
49.
Souvatzoglou M. Krause, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193–200.PubMedCrossRef
50.
Jereczek-Fossa B, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14–7.PubMedCrossRef
51.
Jereczek-Fossa B, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–97.PubMedCrossRef
52.
Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55.PubMed
53.
Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27–32.PubMedCrossRef
54.
Kishi K, Sonomura T, Shirai S, et al. Reirradiation of paraaortic lymph node metastasis by brachytherapy with hyaluronate injection via paravertebral approach: with DVH comparison to IMRT. Brachytherapy. 2013;12:8–13.PubMedCrossRef
55.
Hövels A, Heesakkers R, Adang E, et al. Cost-effectiveness of MR Lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology. 2009;252:729–36.PubMedCrossRef
Metadata
Title
Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential
Authors
Ansje S Fortuin
Robert Jan Smeenk
Hanneke JM Meijer
Alfred J Witjes
Jelle O Barentsz
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Urology Reports / Issue 3/2014
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0389-7

Other articles of this Issue 3/2014

Current Urology Reports 3/2014 Go to the issue

Prostate Cancer (D Parekh, Section Editor)

Multiparametric Magnetic Resonance Imaging in the Management and Diagnosis of Prostate Cancer: Current Applications and Strategies

New Imaging Techniques (A Atala and A Rastinehad, Section Editors)

The Role of Imaging in the Active Surveillance of Small Renal Masses

Female Urology (K Kobashi, Section Editor)

Fecal Incontinence: The Role of the Urologist

New Imaging Techniques (A Atala and A Rastinehad, Section Editors)

Role of Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer

New Imaging Techniques (A Atala and A Rastinehad, Section Editors)

Real-Time Elastography for the Detection of Prostate Cancer

Prostate Cancer (D Parekh, Section Editor)

Prostate Cancer Nomograms: A Review of Their Use in Cancer Detection and Treatment